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Radiotherapy (RT) with ionizing irradiation is commonly used to locally attack tumors. It
induces a stop of cancer cell proliferation and finally leads to tumor cell death. During the
last years it has become more and more evident that besides a timely and locally restricted
radiation-induced immune suppression, a specific immune activation against the tumor
and its metastases is achievable by rendering the tumor cells visible for immune attack.
The immune system is involved in tumor control and we here outline how RT induces anti-
inflammation when applied in low doses and contributes in higher doses to the induction of
anti-tumor immunity.We especially focus on how local irradiation induces abscopal effects.
The latter are partly mediated by a systemic activation of the immune system against the
individual tumor cells. Dendritic cells are the key players in the initiation and regulation of
adaptive anti-tumor immune responses.They have to take up tumor antigens and consecu-
tively present tumor peptides in the presence of appropriate co-stimulation.We review how
combinations of RT with further immune stimulators such as AnnexinA5 and hyperthermia
foster the dendritic cell-mediated induction of anti-tumor immune responses and present
reasonable combination schemes of standard tumor therapies with immune therapies. It
can be concluded that RT leads to targeted killing of the tumor cells and additionally induces
non-targeted systemic immune effects. Multimodal tumor treatments should therefore
tend to induce immunogenic tumor cell death forms within a tumor microenvironment
that stimulates immune cells.
Keywords: low and high dose ionizing irradiation, immune modulation, immunogenic cancer cell death, dendritic
cells, abscopal effects, immune therapy, AnnexinA5, hyperthermia
INTRODUCTION
The old theory about immunological tumor control has been
revived in the last decades. Especially preclinical experiments with
immune deficient mice coined the immune editing hypothesis of
cancer. Recombinase-activating gene 2 (RAG2) deficient mice lack
functional T and B cell receptors and develop tumors more quickly
and with greater frequency than immune competent wild-type
mice (Shankaran et al., 2001). The cancer immune editing model
provides a well reflected explanation regarding how cancer cells get
eliminated by the immune system, stay calm (equilibrium phase),
or escape immune surveillance. This knowledge is a valuable basis
for the design of immunotherapies against cancer (Vesely et al.,
2011).
Clinical studies evaluating the frequency of cancer in immune
suppressed patients further support that the immune system is
involved in tumor control (summarized in Mueller, 1999; Zitvogel
et al., 2010). Changes in the surface expression of major histocom-
patibility complex (MHC) I molecules have a major impact on the
prognosis of tumor patients. Since only the tumor peptide/MHC I
complexes are recognized by cytotoxic T lymphocytes (CTLs), the
contribution of the immune system to a successful cancer ther-
apy has become evident. Importantly, the surface modifications of
tumor cells result from the selection pressure (immune editing)
exerted also by cells from the innate and adaptive immune system
(Pages and Kroemer, 2011).
Nowadays the pivotal question is not whether the immune
system contributes to tumor control but rather in which phase
of tumor disease and after which treatment combinations. Since
immune cells cannot cope with big tumor masses, additional ther-
apies are needed to reduce the tumor volume or to render the
cancer cells visible for immune attack. Certain chemotherapeu-
tic agents (CT) and ionizing irradiation (X-ray) that is applied in
radiotherapy (RT), mostly in combination with further immune
stimulation, may render the tumor cells immunogenic. We assume
that low and high doses of X-ray modulate the immune system and
focus on abscopal anti-tumor immune responses that are induced
by combinations of standard tumor with immune therapies.
IMMUNE MODULATION BY LOW AND INTERMEDIATE DOSE
RADIATION
Exposure to radiation always has been a point of concern for many
people, especially in times when nuclear power plant accidents
occur. Radiation is often associated with being a threat to humans
causing cancer and other diseases. Another rising source of radia-
tion is medical applications. The latter increased the total effective
collective dose of irradiation to humans by 70% over the last years
www.frontiersin.org July 2012 | Volume 2 | Article 75 | 1
Rubner et al. Radiation-induced anti-tumor immunity
[United Nations Scientific Committee on the Effects of Atomic
Radiation (UNSCEAR) Report 2008]. Fortunately, the effects of
radiation on the immune system being a first line defense system
against malignancy have attracted the notice of researchers and
clinicians.
LOW DOSE RADIOTHERAPY INDUCES ANTI-INFLAMMATION – THE
ROLE OF MACROPHAGES
One should distinguish between high dose (single-dose>1.0 Gy),
intermediate dose (single-dose >0.1 and ≤1.0 Gy), and low dose
radiation (≤0.1 Gy; Salomaa et al., 2010). Low and intermedi-
ate dose radiation (low dose RT, LDR) is used to treat acute
and chronic painful inflammatory diseases. LDR induces anti-
inflammation by, e.g., hampering leukocyte adhesion to endothe-
lial cells (ECs), induction of apoptosis, reducing the activity of
the inducible nitric oxide synthase, and by lowering the oxidative
burst in macrophages (summarized in Rodel et al., 2012).
Monocytes and macrophages are key players in initiation,main-
tenance, and resolution of inflammation (Fujihara et al., 2003;
Hume, 2006; Valledor et al., 2010). They support the inflamma-
tory host response by secreting pro-inflammatory cytokines such
as tumor necrosis factor (TNF)α, interleukin (IL)-1β, and IL-6.
The immune response is further amplified by release of reactive
oxygen species (ROS) and nitric oxide (NO). On the other hand
they may initiate the healing process and are involved in resolu-
tion of inflammation by phagocytosis of apoptotic cells and cell
residues as well as by secreting anti-inflammatory cytokines such
as IL-10 and transforming growth factor (TGF)β (Martin and Lei-
bovich, 2005; Anders and Ryu, 2011). Inappropriate regulation
of the resolution process can result in severe chronic inflamma-
tion and autoimmune diseases. Improvements of inflammatory
diseases and pain after LDR have been observed in patients for
over 100 years (summarized in Kern et al., 1999). This suggests
that macrophage-mediated modulations of inflammation can be
influenced by LDR.
Macrophages are considered to be radio-resistant while mono-
cytes are more sensitive to radiation (Hildebrandt et al., 1998;
Bauer et al., 2011). Monocytes are impaired in DNA double-
strand break (DSB) repair; however even their apoptotic rate
merely increased up to 10% following LDR (≤1.0 Gy). It there-
fore can be assumed that the anti-inflammatory effects of LDR
are not caused by dying phagocytes themselves (Voll et al., 1997),
but rather by regulatory mechanisms. Discontinuous dose depen-
dence with local peaks within a dose range of 0.3–0.7 Gy has been
observed in many assay systems where macrophages were exposed
to LDR.
X-ray treatment with single-doses between 0.3 and 0.6 Gy
reduces the production of ROS by activated macrophages. ROS
enhances the destruction of pathogens, but could also lead to
serious destructions of own tissue, if deregulated like in chronic
inflammation and autoimmune diseases (Schaue et al., 2002). Fur-
ther, a reduced activity of the inducible Nitric Oxide Synthase
(iNOS) and a lowered concentration of its immune regulatory
product NO take place in activated macrophages following LDR.
The changes occurred on protein and not on mRNA level (Hilde-
brandt et al., 1998, 2003; Rodel et al., 2002). NO is a key mediator
of cytotoxic and immune stimulating effects. It is produced and
secreted by inflammatory macrophages. A significant inhibition of
NO production in macrophages was observed after LDR, while X-
rays with doses≥5 Gy increased it (Hildebrandt et al., 1998, 2003).
Since NO influences the expression of inflammatory cytokines
(Abramson et al., 2001), it may serve as a link between LDR and
inflammatory cytokine expression.
Decreased levels of the pro-inflammatory cytokine TNFα were
measured when Lipopolysaccharide (LPS)-activated macrophages
were irradiated with 0.5 or 0.7 Gy of X-rays (Tsukimoto et al.,
2009; Rodel et al., 2012). An involvement of the ERK1/2 and p38-
MAPK pathways in triggering such anti-inflammatory responses
is likely. Both pathways are deactivated by dephosphorylation via
the protein phosphatase MKP-1. Tsukimoto et al. (2009) reported
that 0.5 Gy of γ-irradiation significantly increases the expres-
sion of MKP-1, inactivates p38-MAPK, and finally suppresses the
TNFα production in mouse RAW264.7 macrophages. Actually
many of such anti-inflammatory properties of LDR are regu-
lated by nuclear factor kappa-light-chain-enhancer of activated
B cells (NFκB) on a transcriptional level. A reduced translocation
of NFκB into the nucleus has been observed in various inflamma-
tion models after exposure to LDR (summarized in Rodel et al.,
2012).
The amount and nature of cytokines which are produced and
released by macrophages following LDR also depend on the pres-
ence of dying cells in the microenvironment. Activated mono-
cytes/macrophages secrete anti-inflammatory cytokines (IL-10,
TGFβ), rather than pro-inflammatory ones (IL-1β, TNFα) in the
presence of apoptotic cells (Voll et al., 1997). The apoptotic rate of
peripheral blood mononuclear cells (PBMCs) increased following
LDR with a maximum in the dose range of 0.3–0.7 Gy (Kern et al.,
1999). The clearance of such apoptotic cells and/or cell residues
is predominantly carried out by macrophages. More information
on how LDR influences the phagocytosis of apoptotic and necrotic
cells is urgently needed. First investigations with latex beads as prey
revealed that low dose X-irradiation of LPS-activated macrophages
reduces the phagocytosis. In contrast, higher single-doses (≥5 Gy)
slightly increase the uptake of beads by activated macrophages
(Conrad et al., 2009). The phagocytosis of colorectal tumor cells
by macrophages and dendritic cells was shown to be reduced when
the tumor cells (and not the macrophages) had been irradiated
with higher doses of X-ray (2, 5, or 10 Gy). It should be stressed
that the phagocytosis can be significantly enhanced when X-ray is
combined with heat treatment (hyperthermia) of the tumor cells
(Schildkopf et al., 2011).
Such impacts of LDR on macrophages, displaying repeatedly
local peaks in a dose range of 0.3–0.7 Gy, could be a consequence
of one central process affected by LDR. Also in other immune cells
such as PBMCs, polymorphonuclear cells (PMNs), and ECs sim-
ilar immune modulations induced by LDR have been observed,
including a discontinuous dose-dependent translocation of NFκB
into the nucleus (Prasad et al., 1994, 1995; Kern et al., 1999; Roedel
et al., 2002;Rodel et al., 2004a,b, 2009; Gaipl et al., 2009). Since
NFκB is a key transcription factor for a variety of immune fac-
tors such as cytokines, adhesion molecules, and growth factors
and additionally is a potent post-transcriptional regulator of iNOS
(Vodovotz and Bogdan, 1994), its modulation may therefore play a
prominent role in the induction of an anti-inflammatory response
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following LDR. We have recently reported that a reduced secre-
tion of IL-1β by stimulated macrophages after exposure to LDR
correlates with a reduced nuclear translocation of p65 (RelA) of
the NFκB-complex (Lodermann et al., 2012). Nevertheless, LDR
has been shown in experimental animal models to temporarily
suppress immune functions by a variety of other mechanisms.
Examples are the disturbance of cells of the cellular and humoral
immunity or the reduction of the viability of mature blood cells
by affecting the hematopoiesis (Yagunov et al., 1998; Serhatlioglu
et al., 2004).
LDR STIMULATES IMMUNE FUNCTIONS
Other experiments link chronic and acute irradiation with low and
intermediate doses with an enhanced immune function (Liu et al.,
1987; James and Makinodan, 1988; Liu, 2007). Liu and colleagues
showed that a variety of immune functions are stimulated by LDR
such as natural killer (NK) cell and macrophage activity, or pro-
liferation of T cells. Another feature of chronic exposure to LDR
is the induction of an altered cytokine profile in the peripheral
blood that can arise from activation of innate immune responses
and not from changing the total number of white blood cells, red
blood cells, and platelets (Shin et al., 2010).
The enhanced immune functions induced by LDR could
explain why whole body LDR exposure of mice can reduce tumor
outgrowth of B16 melanoma and Lewis lung cancer as well as
metastasis formation after tumor cell inoculation (Hosoi and
Sakamoto, 1993; Liu, 2003). Furthermore, the carcinogenic effect
of high dose irradiation can be suppressed by a previous whole
body irradiation with a dose of 0.075 Gy in C57BL/6 mice to a
certain extent, mostly likely due to LDR-induced immune activa-
tion against tumor cells (Ina et al., 2005). These findings could
shed some light on why people who are exposed to LDR by
a higher background of earth radiation or through work sit-
uation display a decreased incidence for certain cancers or an
elevated life span. This hypothesis is further supported by epi-
demiological studies, such as the British nuclear workers 51 year
study (McGeoghegan and Binks, 2001; Atkinson et al., 2004) or
the Hanford downwind inhabitants 50 years’ survey (Boice et al.,
2006).
The knowledge that LDR also activates immune functions is not
only helpful for radiation safety questions and associated guide-
lines, but also for clinical applications where cancer patients are
treated with high dose radiation therapy (RT). A hint that whole
body irradiation with LDR could improve the effects of standard
RT is provided by animal studies of Jin and colleagues. They com-
pared a fractionated local RT of 6× 5 Gy of Lewis lung cancer
in C57BL/6 mice with a modified fractionated RT in which the
second/fifth and third/sixth fraction of the locally applied irradi-
ation with 5 Gy was substituted by a whole body irradiation with
0.075 Gy (Jin et al., 2007). Since the tumor outgrowth reflecting
the therapeutic effect was comparable in both schemes, the total
irradiation dose could be reduced by two-third when LDR was
included. In another experiment, a radiation scheme of 6× 2 Gy
over 2 weeks was compared with a local 2 Gy irradiation and a dou-
ble administrated whole body irradiation with 0.075 Gy, which was
given twice in the same time frame [2×(2 Gy+ 0.075 Gy× 2)]. In
this case, a significant slower tumor outgrowth in the whole body
irradiated group of mice was observed, although the total dose was
reduced to one-third (Jin et al., 2007).
IMMUNE ACTIVATION BY HIGH DOSE RADIATION
The immune stimulating potential of high dose radiation does
initially not appear obvious since RT induces a time-restricted
immune suppression by directly destroying immune cells (Ander-
son and Warner, 1976). However, in contrast to CT, the immune
suppressive effects of RT are lower and more localized (Hodge
et al., 2008). Nevertheless, CT and RT can both signal to the
immune system tumor cells that had previously escaped immune
surveillance (Ma et al., 2010). The phenotype of cancer cells has
to be modified by therapeutic tools in a way that immune cells
are attracted, induced to mature, and activated. For example, RT
enhances the degradation of existing proteins inside the cells and
also concomitantly the surface expression of MHC class I mol-
ecules (Reits et al., 2006). Complexes of MHC I molecules with
peptides are recognized by CTLs that specifically kill tumor cells.
RT further promotes the priming of antigen-specific DCs (Lee
et al., 2009) and may increase the number of antigen presenting
cells within tumor-draining lymph nodes (LN; Lugade et al., 2005)
where antigen presentation by DCs and activation of CD8+ CTLs
takes place.
IMMUNOGENIC TUMOR CELL DEATH
It was shown that higher radiation doses are associated with
increased antigen expression (Santin et al., 1997) and induction
of necrotic forms of tumor cell death (Mantel et al., 2010). Since
necrotic cells have lost their membrane integrity, formerly hid-
den molecules such as DNA, chaperones, and proteins involved
in stabilization of the DNA are released (Beyer et al., 2012).
They operate as damage-associated molecular patterns (DAMPs)
or alarmins and alert the immune system that “danger” has
occurred (Matzinger, 1994). The immunogenicity of necrotic cells
is strongly determined by the danger signals high-mobility group
box 1 protein (HMGB1) and heat shock protein 70 (Hsp70). How-
ever, also CT- and/or RT-induced apoptotic tumor cells can be
rendered immunogenic besides exerting their phosphatidylser-
ine (PS)-dependent anti-inflammatory effects (Frey and Gaipl,
2011). The expression of the endoplasmic reticulum (ER)-derived
protein calreticulin (CRT) on the tumor cell surface acts as recog-
nition and uptake signal for DCs (Obeid et al., 2007). Further,
Hsp70 is released within membranous structures after stressing
the cells (Vega et al., 2008). The release of such microvesicles
shows strong similarities to those of danger signals. Both events
occur during cell death and may lead to stimulation of distinct
Toll-like receptors (TLRs) on DCs (Pisetsky et al., 2011). RT-
induced necrotic and apoptotic tumor cells may finally stimulate
systemic innate (NK cell-mediated) and adaptive (DC and CTL-
mediated) immunity against the tumor (Figure 1). Immunogenic
tumor cell death induced by RT alone or in combination with fur-
ther immune stimulation is one elicitor of abscopal anti-tumor
responses (summarized in Frey et al., 2012).
ABSCOPAL ANTI-TUMOR EFFECTS
This conclusion is supported by clinical observations showing
that RT achieves not only local tumor control by stopping the
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FIGURE 1 | Ionizing radiation modifies the tumor cell phenotype and
induces a tumor microenvironment that fosters innate and adaptive
immune responses against the tumor. Viable tumor cells or cells of the
tumor microenvironment, as exemplarily displayed here for macrophages,
modify their phenotype when exposed to X-rays (A). LDR leads to reduced
secretion of inflammatory cytokines by macrophages and induces an
anti-inflammatory environment (i). It additionally conditions the tumor for
further treatment with higher doses of X-ray (ii). The latter are applied in RT as
part of cancer treatment and induce distinct forms of tumor cell death (1).
Early apoptotic tumor cells expose CRT, a recognition molecule for their
phagocytosis by DCs. Late apoptotic cells release blebs that carry danger
signals such as Hsp70 and thereby activate DCs. Necrotic tumor cells have
lost their membrane integrity and therefore release immune activating danger
signals (e.g., HMGB1 and Hsp70) that interact with receptors such as TLR and
Hsp-R on DCs. Necrotic cells might also directly be induced by combination of
stress stimuli such as RT and HT (B) or be secondary necrotic ones when the
uptake of apoptotic tumor cells by macrophages is blocked with AnxA5 (B).
The distinct forms of dying and dead tumor cells create an immune
stimulatory tumor microenvironment (displayed in light gray) that fosters
tumor antigen uptake and maturation of DCs (2). The latter process tumor
antigens and (cross-) present tumor peptides via MHC class I and class II
molecules to CD8+ and CD4+T cells, respectively (3). CD8+ CTLs recognize
tumor peptides presented in MHC class I molecules on tumor cells and
specifically attack therapy-modified tumor cells (4a) as wells as non-treated
ones (4b). The tumor microenvironment and the tumor cells resulting from RT
and further immune stimulation may further directly activate NK cells (5)
against the tumor (5a and b). Abbreviations: AnxA5, AnnexinA5; CRT,
calreticulin; DC, dendritic cell; Hsp70, heat shock protein 70; Hsp-R, Hsp
receptor; HMGB1, high-mobility group box 1 protein; HT, hyperthermia; LDR,
low dose radiotherapy; LN, lymph node; NK cell, natural killer cell; RT,
radiotherapy with high single-doses applied in tumor therapy; TLR, Toll-like
receptor; X-ray, ionizing radiation.
proliferation of and destroying the tumor cells directly at the irra-
diated site, but additionally results in indirect anticancer effects
in non-irradiated areas of the patients. Abscopal effects in the
clinics have been observed for various cancer types including
hepatocellular carcinoma (Ohba et al., 1998; Okuma et al., 2011),
chronic lymphocytic leukemia (Sham, 1995), renal cell carcinoma
(Wersall et al., 2006), malignant lymphomas (Nobler, 1969; Anto-
niades et al., 1977), and melanomas (Kingsley, 1975; Postow et al.,
2012).
The phenomenon“abscopal effect”or“distant bystander effect”
was originally described by Mole (1953) and the term comes from
the latin“ab-” (position away from) and“scopus” (mark or target).
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Mole defined it “at a distance from the irradiated volume, but
within the same organism.” In contrast to the radiation-induced
bystander effect, which is mediated via cell-to-cell gap junctions
(Azzam et al., 2001) or by secreted soluble factors (TGFβ, NO; Iyer
et al., 2000) of irradiated cells that thereby communicate with non-
irradiated neighboring (bystander) cells, the abscopal effect is an
indirect and systemic effect in non-irradiated areas distant of the
irradiated field. Taken together, ionizing radiation induces both
local (targeted and bystander effects) and systemic effects (absco-
pal effects) in cancer patients. However, the cellular and molecular
mechanisms of abscopal effects still remain to be clarified.
Various preclinical and clinical studies sustain the assumption
that a spontaneous regression of tumors, metastases, or enlarged
LN outside of the irradiated field is mediated by the immune sys-
tem. Konoeda observed an abscopal effect in metastatic LN of
breast carcinoma in 15 out of 42 patients. The effect was most fre-
quently noticed when infiltrating CD4+ and CD8+ T cells were
present around degenerated tumor cells of the irradiated primary
tumor (Konoeda, 1990). Spontaneous regression of a relapsed
nodular lesion in a patient with NK cell lymphoma without any
treatment was documented by Isobe et al. (2009) after massive
infiltration of CD8+ CTLs in the relapsed lesion. Interestingly,
the patient was initially treated with radio- and chemotherapy
against an eyelid tumor. The susceptibility of tumor cells to CTL-
mediated lysis may result from the RT-induced altered tumor cell
phenotype associated with increased expression of MHC class I
molecules on the surface and an increased intracellular peptide
pool (Reits et al., 2006). Demaria et al. (2004) have actually demon-
strated in a mouse model of mammary carcinoma that the systemic
anti-tumor effect is mediated by the immune system. T cells are
required for distant tumor inhibition after combined therapy of
the primary tumor with RT and the DC growth factor Fms-like
tyrosine kinase receptor 3 ligand (Flt3-L). They concluded that
RT alone is a poor inducer of abscopal effects, but that combi-
nations with further immune stimulants are more effective. In
their preclinical examinations, the Flt3-L increased the number
of DCs at the tumor site. There, DCs assimilate tumor antigens
for tumor peptide (cross)-presentation. Maturation signals for
DCs are delivered in form of cytokines or other inflammatory
stimuli released by the damaged cancer cells resulting after RT
(Demaria et al., 2004). In summary, local RT damages tumor cells
and generates large amounts of tumor antigens in apoptotic and
necrotic tumor cells as well as cellular debris, which, either alone or
together, provide immune stimulatory signals for DCs (Figure 1).
The latter mature and migrate to draining LN, where they present
tumor peptide antigens to naïve T cells. RT further increases the
number of interferon (INF)-γ producing T cells in draining LN
(Lugade et al., 2005). Despite this, Kim and co-workers demon-
strated, in accord with Demaria et al. that conventional RT alone
is not sufficient to eliminate tumor masses distant from the irradi-
ated site. The reason could be an inadequate antigen presentation
in LN which they overcome by injection of DCs into the irradi-
ated tumor tissue (Kim et al., 2004). Anti-tumor immunity can
further be potentiated with an additional administration of the
DC danger/maturation signals LPS or TNFα.
The studies outlined above indicate that a proper DC matu-
ration and activation is essential for the induction of an effective
anti-tumor T cell response. Apetoh and colleagues identified the
TLR4 as one crucial receptor on DCs stimulating the cross-priming
of CD8+CTLs. In addition to LPS, TLR4 also recognizes HMGB1,
a nuclear protein passively released as danger signal by late apop-
totic or necrotic cells (Apetoh et al., 2007). Using a similar experi-
mental design as Kim et al. (2004), Akutsu et al. (2007) identified
the heat shock protein gp96 as a target molecule involved in the
abscopal effect. Radiation-induced gp96 is capable to activate DCs
via TLR2 and TLR4 (Vabulas et al., 2002). Based on the studies of
Lee et al. (2009), Shiraishi et al. (2008), and Dewan et al. (2009),
Takeshima et al. showed that CD8+ T cells play a major role in
growth inhibition of non-irradiated tumors in combining Th1 cell
therapy with local RT. This combination of RT with immune ther-
apy did not only induce the generation of tumor-specific CTLs at
the primary tumor site and complete eradication of the tumor, but
also prevented the outgrowth of distal tumors (Takeshima et al.,
2010).
Likewise combinations of RT with cytokine therapy have the
potential to control metastases. The local and systemic effect
of ECI301, a human macrophage inflammatory protein-1 alpha
variant, in combination with RT was investigated by Shiraishi
and colleagues. Their results indicate that the combined therapy
reduces the primary tumor growth at the irradiated site and that of
distal, non-irradiated tumors. This abscopal effect was dependent
of CD8+ lymphocytes, CD4+ lymphocytes, and NK1.1 cells, but
independent of the tumor-type and genetic background (Shiraishi
et al., 2008). An additional administration of Interleukin-2 (IL-2)
to RT also results in a better local tumor control and regression
of the not irradiated tumor within the same mouse (Everse et al.,
1997; Jurgenliemk-Schulz et al., 1997). Others demonstrated an
abscopal effect after manipulation of tumor cells with transgenes
expressing several cytokines such as IL-2 (Kwong et al., 1997) or
Flt3-L (Dong et al., 2003).
Combinations of RT with antibodies blocking inhibitory neg-
ative regulatory molecules on T cells, such as the monoclonal
antibody ipilimumab against CTLA-4, are promising to induce
systemic anti-tumor immune responses (Dewan et al., 2009).
Ipilimumab was approved by the FDA (U.S. Food and Drug
Administration) in 2011. In two randomized phase 3 trials, an
overall survival benefit in patients with metastatic melanoma was
observed (Hodi et al., 2010; Robert et al., 2011). However, autoim-
mune reactions have to be kept into mind as possible severe side
effect of such combined therapies (Mellman et al., 2011). Table 1
summarizes the literature about abscopal effects observed in pre-
clinical and clinical studies after RT and/or immune therapy. It has
to be stressed that until today only one major hint for a molecular
mechanism for RT-induced abscopal effects has been suggested.
Camphausen and co-workers showed that p53 and downstream
signals are key mediators of this process. In contrast to the studies
mentioned above, a dose-dependent abscopal effect induced by
RT alone was observed in wild-type but not in p53 knockout mice
(Camphausen et al., 2003).
In conclusion, cancer treatments which activate enough DCs
and eventually the adaptive immune system and further directly
cells of the innate immune system (see below) are promising
approaches to improve the eradication of primary tumors and
metastases (Figure 1). An optimized radiation regimen combined
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with immune therapy makes indeed anticancer therapies more
efficient.
ANTI-TUMOR IMMUNITY INDUCED BY COMBINATION OF RT
WITH FURTHER IMMUNE STIMULATION BY ANNEXINA5 OR
HEAT
Additional approaches to induce a CTL-mediated tumor cell
killing are based on the in vivo activation of DCs, which should
take up tumor antigens and consecutively present tumor peptides
to T cells to achieve co-stimulation. However, macrophages rec-
ognize and phagocytose dying tumor cells swiftly and silently
and thereby remove tumor antigens (Gaipl et al., 2007). They
are recruited by find-me signals such as lysophosphatidylcholine
(Lauber et al., 2003) secreted by RT-induced apoptotic cells. The
latter may even cause caspase 3-dependent tumor cell repopu-
lation by generating potent growth-stimulating signals (Huang
et al., 2011). Moreover, an anti-inflammatory milieu results from
the clearance of those apoptotic cells by macrophages (Lauber
et al., 2011). Since DCs and macrophages partly utilize differ-
ent clearance mechanisms (Hoves et al., 2011), one possibility
to enable enhanced access of DCs to RT-induced apoptotic and
necrotic tumor cells is to block their clearance by macrophages
with the PS-binding protein AnnexinA5 (AnxA5; Bondanza et al.,
2004; Frey et al., 2009). The growth of syngeneic tumors is signif-
icantly retarded by a single injection of AnxA5 around the tumor.
Combination of RT with AnxA5 resulted in the most effective
inhibition of tumor growth (Frey et al., 2009). In vivo experi-
ments with immune competent mice bearing syngeneic tumors
have proven that AnxA5 increases the immunogenicity of tumor
cells. The injection of irradiated tumor cells pre-incubated with
AnxA5 cured established tumors in about 50% of the animals,
while the injection of irradiated tumor cells only resulted in less
than 10% of tumor free mice (Bondanza et al., 2004). Since RT
induces tumor cell death and thereby the exposure of PS on
dying tumor cells and on tumor blood vessels, it represents an
adequate combination partner with PS-targeting agents such as
AnxA5, and monoclonal antibodies such as the murine 2aG4
antibody (He et al., 2007). Phase I and II clinical trials with
bavituximab, the human analog to 2aG4, in combination with
standard therapies for the treatment of solid tumors are currently
performed (Derose et al., 2011). In preclinical rat models, combi-
nation of PS-targeting with RT resulted in long-term anti-tumor
immunity even against glioblastoma in over 10% of the animals
(He et al., 2009). Recently Riedl et al. (2011) showed that PS is
also exposed by non-dying tumor cells, preferentially in metas-
tases. Targeting of PS on therapy-induced dying and on viable
metastatic cells could therefore both lead to efficient anti-tumor
immune responses by promoting uptake of the tumor cells by
DCs, to mention here one of multiple possible modes of action
resulting from the shielding of PS (summarized in Frey et al.,
2012).
Cross-presentation of tumor peptides by DCs requires antigen
uptake and additionally a maturation signal for DCs to avoid tol-
erance induction. The maturation of immune stimulatory DCs is
stimulated by necrotic tumor cells (Sauter et al., 2000). Extracel-
lular heat shock proteins act as immune activating danger signals
and fulfill both functions: they are means of transport for tumor
antigens and elicitors of DC maturation (Basu et al., 2000; Somer-
san et al., 2001). Appropriately, DCs pulsed with tumor cells that
have been heat-shocked mediated a significant enhanced cellu-
lar T cell cytotoxicity response against the tumor cells compared
to pulsed DCs with lysates of non-heat-shocked cells (Schueller
et al., 2003). In addition, combination of RT with HT increased
the amount of released danger signals such as HMGB1 and Hsp70
and further fosters the maturation of DCs (Schildkopf et al.,
2009a,b, 2011; Figure 1). Future research should focus on pre-
clinical in vivo models to examine which immune cell subsets
get recruited into the tumor after local treatment with RT plus
HT and under which treatment combinations the maximum DC-
mediated and MHC-dependent CTL activation takes place. Chen
et al. (2009) have already demonstrated in mouse models that
heat-stressed tumor cells are capable of initiating anti-tumor
immune responses by inducing activation of DCs. Immunolog-
ical back-up or parallel mechanisms for tumor cell killing should
be considered, since tumor cells often shed MHC I molecules. The
exposure of Hsp70 on the tumor cell surfaces serves as a recog-
nition signal for activated NK cells (Stangl et al., 2008). NK cells
are activated against the tumor when tumor cells have shed MHC
class I molecules to escape killing by CTLs, since the inhibitory
receptors of NK cells are no longer triggered by MHC I mol-
ecules. Following HT treatment, NK cells have been found to
be enriched at the tumor site (Burd et al., 1998), showing that
innate immune responses also contribute to the fight against the
tumor.
OUTLOOK
We have outlined that immunogenic tumor cell death forms are
induced by RT with additional immune stimulation. Figure 1
schematically depicts how ionizing radiation (X-ray) could stimu-
late innate and adaptive immune responses against the irradiated
tumor as well as against non-irradiated ones (abscopal effects). The
current knowledge suggests that induction of tumor cell necrosis
including necroptosis (Vanlangenakker et al., 2012) and apopto-
sis by RT and further immune stimulators is most beneficial for
the induction of a specific and long-lasting anti-tumor immunity
(Kepp et al., 2009). Since the phenotype of the individual tumor
of a distinct patient is modified by RT, the best possible person-
alized treatment approach is realized. Although tumor regression
is often the main indicator for a successful therapy, this may not
always translate into improved survival rates. Since the immune
system needs time to act, the success of immune therapies is often
observed at later time points after the treatment and connected to
long-term survival rates, as shown in clinical trials with the CTLA-
4-blocking antibody ipilimumab (Mellman et al., 2011). Since
in vivo assays revealed that DCs require approximately 48 h for
migration into the tumor, tumor antigen uptake, maturation, and
consecutive migration to the sentinel lymph node (Wheeler et al.,
2004), innovative irradiation schemes could be that hypofraction-
ated ones expand the days where no irradiation takes place. This
could avoid that activated DCs in the tumor microenvironment
are killed by RT. Further studies are needed to document which
combinations of RT and immune therapies and which time win-
dows of combination are most effective to induce specific and
long-lasting anti-tumor immune responses.
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